Literature DB >> 17180637

Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language.

F S Neves1, J C B Moraes, S C Kowalski, C Goldenstein-Schainberg, L V Lage, C R Gonçalves.   

Abstract

The Behçet's Disease Current Activity Form (BDCAF) is a clinical instrument used to assess the activity of Behçet's disease (BD), which was originally developed in English. The aim of the present study was to perform a cross-cultural adaptation of the BDCAF to Brazilian Portuguese language and to evaluate its reliability in a population of Brazilian patients with BD. Brazilian Portuguese version of the BDCAF, named BR-BDCAF, was obtained according to established guidelines. Forty Brazilian patients with BD diagnosed according to the International Study Group for Behçet's Disease criteria were assessed by two rheumatologists in independent sessions and submitted to the BR-BDCAF. Inter- and intraobserver agreement were then evaluated by kappa scores (values higher than 0.6 indicated good agreement). Good inter- and intraobserver agreements were achieved for the most common manifestations of BD: kappa scores higher than 0.6 were obtained for oral and genital ulcerations, skin lesions, and articular and general complaints. Moderate interobserver agreement was obtained for ocular activity (kappa 0.483) and fair interobserver agreement was obtained for gastrointestinal (kappa 0.322), major vessel (kappa 0.281), and central nervous system activity (kappa 0.304). BR-BDCAF was found to be a reliable instrument for the classic mucocutaneous and articular manifestations of BD and for general complaints, but complementary assessment is needed to evaluate specific visceral involvement for disease activity.

Entities:  

Mesh:

Year:  2006        PMID: 17180637     DOI: 10.1007/s10067-006-0484-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  12 in total

Review 1.  Behçet's disease.

Authors:  T Sakane; M Takeno; N Suzuki; G Inaba
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

Review 2.  Guidelines for the process of cross-cultural adaptation of self-report measures.

Authors:  D E Beaton; C Bombardier; F Guillemin; M B Ferraz
Journal:  Spine (Phila Pa 1976)       Date:  2000-12-15       Impact factor: 3.468

3.  Evaluation of the Turkish translation of a disease activity form for Behçet's syndrome.

Authors:  V Hamuryudan; I Fresko; H Direskeneli; M J Tenant; S Yurdakul; T Akoglu; H Yazici
Journal:  Rheumatology (Oxford)       Date:  1999-08       Impact factor: 7.580

4.  Behçet's disease: evaluation of a new instrument to measure clinical activity.

Authors:  B B Bhakta; P Brennan; T E James; M A Chamberlain; B A Noble; A J Silman
Journal:  Rheumatology (Oxford)       Date:  1999-08       Impact factor: 7.580

Review 5.  Behçet syndrome.

Authors:  Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal:  Curr Opin Rheumatol       Date:  2004-01       Impact factor: 5.006

6.  The Behcet's disease activity index.

Authors:  G Lawton; B B Bhakta; M A Chamberlain; A Tennant
Journal:  Rheumatology (Oxford)       Date:  2003-07-30       Impact factor: 7.580

Review 7.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

Review 8.  Behçet's syndrome--classification criteria.

Authors:  C G Barnes
Journal:  Ann Med Interne (Paris)       Date:  1999-10

Review 9.  Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.

Authors:  F Guillemin; C Bombardier; D Beaton
Journal:  J Clin Epidemiol       Date:  1993-12       Impact factor: 6.437

10.  Quality of life and life satisfaction in patients with Behçet's disease: relationship with disease activity.

Authors:  Hatice Bodur; Pinar Borman; Yildiz Ozdemir; Ciğdem Atan; Gülcan Kural
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

View more
  17 in total

1.  Immunometabolic biomarkers of inflammation in Behçet's disease: relationship with epidemiological profile, disease activity and therapeutic regimens.

Authors:  L Cantarini; V Pucino; A Vitale; R Talarico; O M Lucherini; F Magnotti; V De Rosa; M Galgani; C Alviggi; G Marone; M Galeazzi; G Matarese
Journal:  Clin Exp Immunol       Date:  2016-02-24       Impact factor: 4.330

2.  Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease.

Authors:  Antonio Vitale; Giacomo Emmi; Giuseppe Lopalco; Claudia Fabiani; Stefano Gentileschi; Elena Silvestri; Di Scala Gerardo; Florenzo Iannone; Bruno Frediani; Mauro Galeazzi; Giovanni Lapadula; Donato Rigante; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2017-04-11       Impact factor: 2.980

3.  Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.

Authors:  Nádia Emi Aikawa; Carla Gonçalves; Clovis Artur Almeida Silva; Célio Gonçalves; Eloísa Bonfá; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2009-12-11       Impact factor: 2.631

4.  Quality of life impairment in Behçet's disease and relationship with disease activity: a prospective study.

Authors:  Claudia Fabiani; Antonio Vitale; Ida Orlando; Jurgen Sota; Marco Capozzoli; Rossella Franceschini; Mauro Galeazzi; Gian Marco Tosi; Bruno Frediani; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2017-06-15       Impact factor: 3.397

5.  Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.

Authors:  Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Giuseppe Lopalco; Lorenzo Vannozzi; Silvana Guerriero; Stefano Gentileschi; Daniela Bacherini; Rossella Franceschini; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2016-12-16       Impact factor: 2.980

6.  Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.

Authors:  Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Lorenzo Vannozzi; Giuseppe Lopalco; Silvana Guerriero; Ida Orlando; Rossella Franceschini; Daniela Bacherini; Luca Cimino; Alessandra Soriano; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Carlo Salvarani; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2016-11-16       Impact factor: 2.980

Review 7.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

8.  Behçet's disease: clinical value of the video capsule endoscopy for small intestine examination.

Authors:  Fabricio Souza Neves; Sônia Nádia Fylyk; Lais Verderame Lage; Shinichi Ishioka; Claudia Goldenstein-Schainberg; Paulo Sakai; Célio Roberto Gonçalves
Journal:  Rheumatol Int       Date:  2008-09-26       Impact factor: 2.631

9.  Neutrophil hyperchemotaxis in Behçet's disease: a possible role for monocytes orchestrating bacterial-induced innate immune responses.

Authors:  Fabricio Souza Neves; Solange Carrasco; Cláudia Goldenstein-Schainberg; Célio Roberto Gonçalves; Suzana Beatriz Veríssimo de Mello
Journal:  Clin Rheumatol       Date:  2009-08-25       Impact factor: 2.980

10.  Faraway from the silk route: demographic and clinical features of Behçet's disease in 106 Brazilian patients.

Authors:  Fabricio Souza Neves; Cezar Augusto Muniz Caldas; Laís Verderame Lage; Cláudia Goldenstein-Schainberg; Célio Roberto Gonçalves
Journal:  Clin Rheumatol       Date:  2009-01-13       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.